Hsbc Holdings PLC Immunovant, Inc. Transaction History

Hsbc Holdings PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $220,910 - $319,579	7,298 New	7,298 $235,000
Q4 2022 Feb 14, 2023	SELL	$6.59 - $17.75 $525,203 - $1.41 Million	-79,697 Reduced 61.64%	49,592 $880,000
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $26,995 - $43,755	6,869 Added 5.61%	129,289 $712,000
Q2 2022 Aug 11, 2022	BUY	$3.38 - $5.65 $42,185 - $70,517	12,481 Added 11.35%	122,420 $486,000
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $24,621 - $42,674	4,866 Added 4.63%	109,939 $615,000
Q4 2021 Feb 11, 2022	BUY	$7.33 - $9.32 $350,264 - $445,356	47,785 Added 83.41%	105,073 $895,000
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $401,588 - $651,364	57,288 New	57,288 $510,000
Q1 2021 May 14, 2021	SELL	$13.08 - $49.6 $103,318 - $391,790	-7,899 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$36.36 - $52.71 $189,835 - $275,198	-5,221 Reduced 39.79%	7,899 $364,000
Q3 2020 Nov 12, 2020	SELL	$22.61 - $38.9 $274,779 - $472,751	-12,153 Reduced 48.09%	13,120 $481,000
Q2 2020 Aug 14, 2020	SELL	$13.87 - $28.44 $48,115 - $98,658	-3,469 Reduced 12.07%	25,273 $615,000
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $240,283 - $492,350	28,742 New	28,742 $447,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.